// App-Quantinova.ai

835 : Mir~17-92 Identifies BCL2 As a Therapeutic Target In BCR-ABL Positive B-Lineage Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Matthias Eder

Principal Investigators

  • Alex Elder

  • David Barzan

  • Oliver G. Ottmann

  • Arnold Ganser

  • Andreas Pich

  • Denise Hilfiker-Kleiner

  • Olaf Heidenreich

  • Michaela Scherr

  • Karin Battmer

  • Simon Bomken

  • Melanie Ricke-Hoch

  • Anke Schroder

  • Letizia Venturini

  • Heike Pfeiffer

  • Helen J Blair

  • Josef Vormoor

Medical Centers

  • Northern Institute for Cancer Research Newcastle University, Newcastle, United Kingdom

  • Dept. Urology and Urologic Oncology, Medical School Hannover, Hannover, Germany

  • Northern Institute for Cancer Research Newcastle University, Newcastle, United Kingdom

  • Department of Experimental Hematology, Hannover Medical School, Hannover, Germany

  • Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle, United Kingdom

  • Dept. Hematology, Hemostaseology, Oncology & Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

  • Department of Medicine, Hematology/Oncology, Goethe University of Frankfurt, Frankfurt, Germany

  • Dept. Hematology, Hemostaseology, Oncology & Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

  • Department of Medicine, Hematology/Oncology, Goethe University of Frankfurt, Frankfurt, Germany

Locations

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • microRNA-17-3p

  • B-cell lymphoma 2

Drug/Treatment

  • Imatinib

  • IkT001

  • L-Tyrosine

  • ABT-737

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved